Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Retatrutide is an investigational triple agonist peptide being developed by Eli Lilly, designed to simultaneously target GLP-1, GIP, and glucagon receptors a mechanism that distinguishes it from currently approved agents such as semaglutide and tirzepatide
To view a copy of this licence, visit About this article Cite this article Kletkiewicz, H., Wojciechowski, M.S
outcomes depend on baseline BMI, diet quality, physical activity, and metabolic response
10.1016/j.biopha.2023.114936 57 ZhangQ.YanL.LuJ.ZhouX
The effects of GH in combination with IGF-I on protein synthesis and the applicability for the treatment of diseases associated with catabolism, particularly those for which GH treatment on its own has proven ineffective, remain to be determined
US$ 20.43
US$ 26.73
US$ 28.94
US$ 20.41
